These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis. Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627 [TBL] [Abstract][Full Text] [Related]
9. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes. Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915 [TBL] [Abstract][Full Text] [Related]
10. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease. Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848 [TBL] [Abstract][Full Text] [Related]
11. Role of Formyl Peptide Receptors and β-Arrestin-1 in suPAR Signal Transduction in Mouse Podocytes: Interactions with αVβ3-Integrin. Kim EY; Dryer SE Cells; 2024 Jan; 13(2):. PubMed ID: 38247863 [TBL] [Abstract][Full Text] [Related]
12. The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective. Benucci M; Damiani A; Russo E; Guiducci S; Li Gobbi F; Fusi P; Grossi V; Amedei A; Manfredi M; Infantino M J Pers Med; 2022 Dec; 12(12):. PubMed ID: 36556207 [TBL] [Abstract][Full Text] [Related]
13. Serum suPAR in patients with FSGS: trash or treasure? Maas RJ; Deegens JK; Wetzels JF Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666 [TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases. Manfredi M; Van Hoovels L; Benucci M; De Luca R; Coccia C; Bernardini P; Russo E; Amedei A; Guiducci S; Grossi V; Bossuyt X; Perricone C; Infantino M J Pers Med; 2023 Apr; 13(4):. PubMed ID: 37109074 [TBL] [Abstract][Full Text] [Related]
18. Soluble urokinase-type plasminogen activator receptor inhibits cancer cell growth and invasion by direct urokinase-independent effects on cell signaling. Jo M; Thomas KS; Wu L; Gonias SL J Biol Chem; 2003 Nov; 278(47):46692-8. PubMed ID: 12963722 [TBL] [Abstract][Full Text] [Related]
19. What is the Role of Soluble Urokinase-Type Plasminogen Activator in Renal Disease? Saleem MA Nephron; 2018; 139(4):334-341. PubMed ID: 29909410 [TBL] [Abstract][Full Text] [Related]